Role of alpha-synuclein, PARP and PAR in the death of neurons (via parthanatos) in PD
 

For those not put off already by the title, Simon does a great job of explaining another piece of the PD puzzle, via the following SoPD blog post:

We’re re-branding: It’s now called PARPinson’s | The Science of Parkinson's

The comment section of this SoPD blog post is also well worth a read. The following link is to an article referred to by Patrik Brundin in one of those comments:

Science Magazine - November 2, 218

Niraparib (zejula) was selected for funding at the most recent Linked Clinical Trials meeting (funding for repurposed drugs). It’s a really effective parp1 inhibitor. It was clearly the most interesting presentation, though a few others were also exciting. Look for announcement of a clinical trial to begin in 2019.

The cartoon of the different forms of cell death is excellent; I knew about some but not all of them.